Peer-Reviewed Journal Details
Mandatory Fields
Tilson L, Sharp L, Usher C, Walsh C, S W, O'Ceilleachair A, Stuart C, Mehigan B, John Kennedy M, Tappenden P, Chilcott J, Staines A, Comber H, Barry M
2011
June
European Journal of Health Economics
Cost of care for colorectal cancer in Ireland: a health care payer perspective
Published
()
Optional Fields
Colorectal cancer Cost Health care resources Chemotherapy
Epub ahead of publication
Objective

Management options for colorectal cancer
have expanded in recent years. We estimated average
lifetime cost of care for colorectal cancer in Ireland in
2008, from the health care payer perspective.


Method


A decision tree model was developed in Microsoft
EXCEL. Site and stage-specific treatment pathways
were constructed from guidelines and validated by expert
clinical opinion. Health care resource use associated with
diagnosis, treatment and follow-up were obtained from the
National Cancer Registry Ireland (n=1,498 cancers diagnosed
during 20042005) and three local hospital databases
(n=155, 142 and 46 cases diagnosed in 2007). Unit costs
for hospitalisation, procedures, laboratory tests and radiotherapy
were derived from DRG costs, hospital finance
departments, clinical opinion and literature review.
Chemotherapy costs were estimated from local hospital
protocols, pharmacy departments and clinical opinion.
Uncertainty was explored using one-way and probabilistic
sensitivity analysis.

Results


In 2008, the average (stage weighted) lifetime cost
of managing a case of colorectal cancer was 39,607. Average
costs were 16% higher for rectal (43,502) than colon
cancer (37,417). Stage I disease was the least costly
(23,688) and stage III most costly (48,835). Diagnostic
work-up and follow-up investigations accounted for 4 and5%
of total costs, respectively. Cost estimates were most sensitive
to recurrence rates and prescribing of biological agents.


Conclusion


This study demonstrates the value of using
existing data from national and local databases in contributing
to estimating the cost of managing cancer. The
findings illustrate the impact of biological agents on costs
of cancer care and the potential of strategies promoting
earlier diagnosis to reduce health care resource utilisation
and care costs.




0.1007/s10198-011-0325-z
Grant Details
Health Research Board